Lombard Medical Announces First Patient Enrolled and Treated in the ALTITUDE Registry for the Altura® Stent Graft System

Get Instant Instagram Followers and Likes with GetInsta

GetInsta App is 100% safe and secure to get benefits from online smart feature plans. There are lots of reliable and smart feature explorations to achieve your objectives. Learn more!

Philips Introduces Integrated Interventional Hemodynamic System with Patient Monitor IntelliVue X3

The integration provides the opportunity for monitoring during image-guided procedures on the Philips Image Guided Therapy System – Azurion, improving workflow with comprehensive patient records that support timely clinical decision-making during interventional cardiology procedures and beyond.

Lawson Health Research Institute Found Simple Device Improves Care After Kidney Transplantation

The geko™ device, manufactured by Sky Medical Technology Ltd and distributed in Canada by Trudell Healthcare Solutions Inc., is a muscle pump activator that significantly improves blood flow by stimulating the body’s ‘muscle pumps.’

“I am encouraged by our positive early clinical experience with Altura. The simplicity of planning, accuracy of deployment and repositionability could lead to it becoming a workhorse device in the future. The ALTITUDE registry will provide a real world evaluation of the longer term outcomes,” said Simon Kreckler, M.D., F.R.C.S., vascular & endovascular surgeon at Addenbrooke’s Hospital, Cambridge, UK.

Lombard Medical, Inc. (NASDAQ: EVAR), a developer, manufacturer and marketer of endovascular aortic aneurysm repair products, today announced that it has enrolled and treated the first patient in its global registry to evaluate its Altura® Endograft System.

The ALTITUDE registry (ALTura Impact on the Treatment of Abdominal Aortic Aneurysms Using a Novel D-stent EVAR Design) is being conducted across a range of UK and international clinical centers to evaluate the use of the Altura Endograft System in 1,000 patients in typical clinical-use conditions.

ALTITUDE’s Chief investigator, Paul Hayes, M.D., F.R.C.S., Department of Surgery, University of Cambridge and Addenbrooke’s Hospital, Cambridge, UK, commented, “This registry will allow the clinical community of AAA implanters to gain necessary experience with Altura. Given the system’s ultra-low profile, its repositionability, the elimination of the contralateral cannulation step and retrograde delivery of the limb sections, this innovative design promises to facilitate a much simpler, faster, more predictable and consistent deployment of the endograft. The launch of this registry confirms Lombard’s confidence in the product and will allow us to develop a robust dataset about long-term outcomes.”

“I am encouraged by our positive early clinical experience with Altura. The simplicity of planning, accuracy of deployment and repositionability could lead to it becoming a workhorse device in the future. The ALTITUDE registry will provide a real world evaluation of the longer term outcomes,” said Simon Kreckler, M.D., F.R.C.S., vascular & endovascular surgeon at Addenbrooke’s Hospital, Cambridge, UK.

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine here.

Related Articles